Division of Endocrinology, University of Buenos Aires, Buenos Aires, Argentina.
Department of Pathology, University of Buenos Aires, Buenos Aires, Argentina.
Arch Endocrinol Metab. 2021 Nov 1;65(2):242-247. doi: 10.20945/2359-3997000000325. Epub 2021 Feb 15.
Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3 to 10 months despite aggressive multidisciplinary management. The presence of targetable mutations in anaplastic thyroid carcinoma patients is an opportunity for treatment when conventional therapeutics approaches are not effective, a frequent situation in the majority of patients. We present our experience in the management of a patient with unresectable anaplastic thyroid cancer who had a remarkable and rapid response to treatment with dabrafenib and trametinib during the COVID-19 pandemic. After four weeks of dabrafenib 150 mg twice daily plus trametinib 2 mg daily, he showed a dramatic reduction of the cervical mass around 90%. Nearly eight weeks under treatment with dabrafenib plus trametinib, the patient remains with minimal locoregional disease without distant metastases.
间变性甲状腺癌是甲状腺最罕见的肿瘤，占临床诊断甲状腺癌的比例不足 2%。通常情况下，它的发病极其迅速，大多数情况下预后极差，即使采用积极的多学科综合治疗，中位总生存期也仅有 3 至 10 个月。间变性甲状腺癌患者存在可靶向的突变，为治疗提供了机会，特别是在大多数患者中，常规治疗方法无效时。在 COVID-19 大流行期间，我们遇到了一位无法切除的间变性甲状腺癌患者，他对达布拉非尼联合曲美替尼治疗有显著且快速的反应，现将我们的治疗经验报告如下。在接受每日两次 150mg 达布拉非尼联合每日 2mg 曲美替尼治疗四周后，他的颈部肿块显著缩小了约 90%。在接受达布拉非尼联合曲美替尼治疗近八周后，患者局部疾病基本稳定，无远处转移。
